期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
CRISPR-Cas9功能基因筛选技术在肝癌研究中的应用 被引量:1
1
作者 曹颖 钱若兰 +2 位作者 杨晨 王存 覃文新 《中国细胞生物学学报》 CAS CSCD 2022年第4期663-671,共9页
肝癌是全球第四大致死肿瘤,对人类健康构成重大威胁。进展期肝癌缺乏有效靶点,以及目前标准疗法治疗效果有待进一步提高,是肝癌研究领域亟待解决的关键科学问题之一。CRISPR-Cas9功能基因筛选技术促进了肝癌生物学研究的发展,借助该技术... 肝癌是全球第四大致死肿瘤,对人类健康构成重大威胁。进展期肝癌缺乏有效靶点,以及目前标准疗法治疗效果有待进一步提高,是肝癌研究领域亟待解决的关键科学问题之一。CRISPR-Cas9功能基因筛选技术促进了肝癌生物学研究的发展,借助该技术,研究者发现了诸多参与肿瘤发生发展的靶基因。此外,无偏倚的CRISPR-Cas9功能基因筛选为探索耐药驱动机制和确定潜在治疗新靶点提供了基础。该文将系统阐述CRISPR-Cas9高通量功能基因筛选技术在肝癌研究领域取得的进展和突破,这些研究将有助于加深人们对肝癌的理解及开辟新的潜在治疗方案。 展开更多
关键词 肝癌 肝细胞癌 CRISPR-Cas9功能基因筛选 肝癌治疗
原文传递
Interactions between the nuclear matrix proteins and the 5'-flanking cis-acting elements of the human ε-globin gene
2
作者 YAN Zhijiang qian ruolan 《Chinese Science Bulletin》 SCIE CAS 1999年第9期808-811,共4页
An erythroid-specific nuclear matrix protein (termed ε-NMP_k) in K562 cells, which can specifically bind to the positive stage-specific regulatory element (ε-PRE Ⅱ, -446—-419 bp) upstream of the human ε-globin ge... An erythroid-specific nuclear matrix protein (termed ε-NMP_k) in K562 cells, which can specifically bind to the positive stage-specific regulatory element (ε-PRE Ⅱ, -446—-419 bp) upstream of the human ε-globin gene, has been identified by using gel mobility shift assay.Meanwhile, Southwestern blotting assay showed that the nuclear matrix protein ε-NMP_k in K562,cells may be composed of two polypeptides ( ~ 40 ku). In addition, it is observed in the gel mobility shift assay that the nuclear matrix proteins from K562, HEL and Raji cells can bind to the silencer DNA ( - 392— -177 bp) in the 5’-flanking sequence of human ε-globin gene respectively. However, the shift band K detected in K562 cells is different from shift band H/R in HEL and Raji cells, suggesting that a common nuclear matrix protein may exist in HEL and Raji cells. Results show that the nuclear matrix protein may play an important role in the regulation of the human ε-globin gene expression. 展开更多
关键词 human ε-globin gene cis-acting element nuclear matrix protein
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部